Paul Efron - Jul 31, 2025 Form 3 Insider Report for Mallinckrodt plc

Role: Director
Signature: /s/ Mark Tyndall, Attorney-in-Fact
Transactions as of: Jul 31, 2025
Transactions value $: $0
Form type: 3
Date filed: 8/4/2025, 08:43 PM
Next filing: Aug 18, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Efron Paul	Director	675 MCDONNELL BLVD., HAZELWOOD	/s/ Mark Tyndall, Attorney-in-Fact	2025-08-04	0002024711

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding		Ordinary Shares						773	Jul 31, 2025	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On July 31, 2025, pursuant to the Transaction Agreement, dated as of March 13, 2025 (as amended, the "Transaction Agreement"), by and among Mallinckrodt plc (the "Issuer"), Endo, Inc. ("Endo") and Salvare Merger Sub LLC, the Issuer's wholly owned subsidiary ("Merger Sub"), the Merger Sub merged with and into Endo (the "Business Combination"), with Endo surviving the Business Combination as a wholly owned subsidiary of the Issuer. At the Merger Effective Time (as defined in the Transaction Agreement), each share of Endo common stock held by the reporting person immediately prior to the Merger Effective Time automatically converted into the right to receive approximately $1.31 in cash and 0.2575 ordinary shares of the Issuer without interest and subject to applicable withholding. The securities reported herein were acquired by the reporting person prior to the reporting person becoming a director of the Issuer.
F2	The reporting person became a director of the Issuer immediately following the effective time of the Business Combination.

Content

On July 31, 2025, pursuant to the Transaction Agreement, dated as of March 13, 2025 (as amended, the "Transaction Agreement"), by and among Mallinckrodt plc (the "Issuer"), Endo, Inc. ("Endo") and Salvare Merger Sub LLC, the Issuer's wholly owned subsidiary ("Merger Sub"), the Merger Sub merged with and into Endo (the "Business Combination"), with Endo surviving the Business Combination as a wholly owned subsidiary of the Issuer. At the Merger Effective Time (as defined in the Transaction Agreement), each share of Endo common stock held by the reporting person immediately prior to the Merger Effective Time automatically converted into the right to receive approximately $1.31 in cash and 0.2575 ordinary shares of the Issuer without interest and subject to applicable withholding. The securities reported herein were acquired by the reporting person prior to the reporting person becoming a director of the Issuer.

The reporting person became a director of the Issuer immediately following the effective time of the Business Combination.

Remarks:

Exhibit 24 - Power of Attorney. This Form 3 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014.